RecruitingNot ApplicableNCT05562505

Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure

A Randomised Controlled Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure

Sponsor

Australian and New Zealand Intensive Care Research Centre

Enrollment

140 participants

Start Date

Nov 28, 2022

Study Type

INTERVENTIONAL

Conditions

COVID-19 Respiratory Infection Pneumonia Mechanical Ventilation Complication Hypoxemia Extracorporeal Membrane Oxygenation Acute Respiratory Distress Syndrome Due to COVID-19

Summary

To determine whether a strategy of adding venovenous ECMO to mechanical ventilation, as compared to mechanical ventilation alone, increases the number of intensive care free days at day 60, in patients with moderate to severe acute hypoxic respiratory failure.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Venovenous ECMO for people with acute respiratory distress syndrome due to covid-19, covid-19 respiratory infection, and other related conditions. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.